Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Shares withheld for taxes Chief Scientific Officer gave up 12,630 shares (to pay taxes)
  2. 4 Shares withheld for taxes Chief Executive Officer gave up 11,917 shares (to pay taxes)
  3. 4 Derivatives Options or other derivatives
  4. 4 Shares withheld for taxes Chief Legal Officer gave up 11,395 shares (to pay taxes)
  5. 4 Planned sale Director sold 10,000 shares at $10.11 ($101,052)
  6. 4 Grant or award Chief Financial Officer acquired 58,869 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Planned sale Director sold 10,000 shares at an average $11.56 ($115,588)
  9. 4 Exercise or conversion Director acquired 36,316 shares (option exercise)
  10. 4 Grant or award Chief Medical Officer acquired 58,386 shares (grant or award)
  11. 4 Grant or award Chief Legal Officer acquired 56,446 shares (grant or award)
  12. 4 Planned sale Director sold 10,100 shares at an average $13.51 ($136,454)
  13. 4 Planned sale Chief Executive Officer sold 100 shares at $15.00 ($1,500)
  14. 4 Grant or award Chief Scientific Officer acquired 60,230 shares (grant or award)
  15. 4 Planned sale Director sold 11,000 shares at $15.05 ($165,495)
  16. 4 Planned sale Chief Executive Officer sold 9,648 shares at $15.04 ($145,106)
  17. 4 Planned sale Director sold 27,590 shares at an average $13.88 ($382,934)
  18. 4 Planned sale Director sold 2,410 shares at an average $13.77 ($33,192)
  19. 4 Grant or award Chief Executive Officer acquired 56,458 shares (grant or award)
  20. 4 Planned sale Director sold 10,000 shares at $11.27 ($112,691)

Page 4 of 22 · 435 filings